Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
P48067
UPID:
SC6A9_HUMAN
Alternative names:
Solute carrier family 6 member 9
Alternative UPACC:
P48067; A6NDH1; A6NII2; A6NNZ8; Q5TAB8; Q5TAB9; Q5TAC0
Background:
Sodium- and chloride-dependent glycine transporter 1, also known as Solute carrier family 6 member 9, plays a crucial role in regulating glycine concentrations at inhibitory glycinergic synapses. This protein's function is essential for maintaining the balance of neural transmission in the central nervous system, highlighting its significance in neurobiology.
Therapeutic significance:
Glycine encephalopathy with normal serum glycine, a severe metabolic disorder, is directly linked to mutations affecting this transporter. Understanding the role of Sodium- and chloride-dependent glycine transporter 1 could open doors to potential therapeutic strategies for treating this debilitating condition.